Reverse Translational Bioinformatics: A Bioinformatics Assay Of Age, Gender And Clinical Biomarkers by Fliss, Amit et al.
   
Reverse Translational Bioinformatics: A Bioinformatics Assay Of Age, 
Gender And Clinical Biomarkers 
Amit Fliss, PhD
1, Micha Ragolsky, MD
2, Eitan Rubin, PhD
1 
1Ben Gurion University, Beer Sheva, Israel; 
2Mental Health Center, Beer Sheva, Israel 
Abstract 
In bioinformatics, clinical data is rarely used. Here, 
we propose using bedsidedata in basic research, via 
bioinformatics    methodologies.  To  demonstrate  the 
potential  of  this  so  called  Reverse  Translational 
Bioinformatics  approach,  classical  bioinformatics 
tools  were  applied  to  blood  biomarker  information 
attained  from  a  large  scale,  open access  cross 
sectional survey. The results of this analysis include a 
novel classification of blood biomarkers, critical ages 
in  which  basic  biological  processes  may  shift  in 
humans,  and  a  possible  approach  to  exploring  the 
gender specificity of these shifts. Changes in normal 
values were also shown to be non linear, with  most 
of  the  non linearity  attributed  to  the  shift  from 
growth  to  maturity.  Together,  these  finding 
demonstrate  that  reversed  translational 
bioinformatics may contribute to basic research. 
Introduction 
Despite  the  fact  that  the  word  'translation'  is  not 
inherently  directional,  Translational  Medicine  (TM) 
is  normally  understood  to  mean  the  translation  of 
scientific  discoveries  made  at  the  bench  to 
improvement  in  bedside  treatment.  Reversed  TM 
involves translation in the reverse direction, namely 
the  flow  of  information  and  knowledge  from  the 
bedside  to  the  bench.  Reversed  TM  is  not  a  new 
branch  of  research;  at  least  57  papers  have  been 
published with the words "bedside to bench" included 
in their title (see for example(1)). In bioinformatics, 
however, this approach is still emerging.  
Given  the  rapid  increase  in  availability  of  data 
generated at bedside, we propose to establish reverse 
Translational BioInformatics (reversed TBI) as a new 
field  that  combines  bioinformatics  and  medical 
informatics. Bioinformatics offers a toolbox suitable 
for analyzing large arrays of noisy, poorly annotated 
and error ridden biological data (e.g. in transcription 
profiling(2) or in proteomics(3)).  Medicine, on the 
other  hand,  brings  measurements  of  a  battery  of 
biomarkers for very large populations. In comparison 
to  medicine,  even  the  largest  efforts  to  measure 
biomarkers  in  mammals  (e.g.,  the  mouse  phenome 
project)  involves  the  measurement  of  only  a  few 
hundred traits in a few hundred animals at one or two 
ages(4). Mining of clinical literature placed medical 
informatics at the forefront of knowledge discovery 
research (5); mining of clinical data may make Homo 
sapiens  an  important  model  system  in  biology  for 
research areas such as individual variability or aging. 
In  clinical  research,  the  use  of  bedside  data  is 
becoming ever more common (see for example (6)), 
although there is an on going debate on the value of 
retrospective studies in making clinical decisions(7). 
But  the  use  of  bedside  data  is  not  without  its 
challenges. It is conceived as inaccessible and/or of 
too poor quality, despite an ever increasing number of 
publications  based  on  bedside  data  (see  for 
example(8)).  Another  source  of  concern  is  the 
uncertainty regarding the suitability of existing tools 
and  methodologies  for  bedside  data.  Will  mining 
these  data  necessitate  the  development  of  new 
methodologies and tools, or will existing tools do? Is 
data quality sufficiently high to justify the effort of 
accessing and analyzing it?  
To  partially  address  these  questions,  we  present  a 
study of the interplay between age, gender and blood 
biomarkers  variation  using  bioinformatics  tools. 
Clinically,  biomarker  variation  during  aging  was 
analyzed  in  an  effort  to  predict  overall  disease 
propensity, with limited success(9). By contrast, the 
variation in blood biomarkers during growth has not 
been characterized to the same extent. For example, a 
recent  analysis of the relationship between age and 
platelet parameters, perhaps the most comprehensive 
and detailed analysis of this relationship to date, does 
not include children under 17 (10). In this paper we 
demonstrate how aging and its interaction with gender 
can be characterized using clinical data from human. 
We  used  the  3rd  National  Health  and  Nutrition 
Examination Survey (NHANES3)  (11)  as a proxy 
for bedside data; the study if aging, blood biomarkers, 
and gender using bioinformatics approaches is used 
to demonstrate of the reverse TBI approach. 
Methods 
DATA  SOURCE:  The  3
rd  National  Health  and 
Nutrition Examination Survey (NHANES3) was used 
as the data source, as no source of bedside data is 
freely and publicly available. NHANES3 was based 
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on  a  random  sample  of  the  non hospitalized  US 
population  comprising  29,314  individuals  (13,980 
males, 15,334 females). The laboratory section of the 
NHANES3 public data release was parsed into a tab 
delimited  text  file,  and  'null  but  meaningful' values 
were  replaced  with  null  values.  The  name  and 
abbreviated label of all the biomarkers are given in 
the legend of Figure 1. 
DATA PROCESSING: Some fields were eliminated 
from  the  original  data:  (1)  irrelevant  fields  (e.g. 
ethnicity  fields  or  sample  weight  fields)  or  fields 
duplicated with different units (e.g., PLPSI and PLP), 
(2) non numeric or non continuous fields (i.e. fields 
with  10  or  less  different  values),  (3)  fields  where 
more than 1/3 of the values in the raw observation are 
missing. Of the original 175 fields, 37 and 38 fields 
remained  (for  males  and  females  correspondingly) 
after this elimination, and were used as biomarkers in 
subsequent  analysis.  After  eliminating  individuals 
missing  over  50%  of  the  biomarker  measurements, 
equal size age gender groups were created including 
150 individuals each. Each bin was considered as a 
single observation, with all the individuals in that bin 
being considered as biological replicas. The mean age 
of  the  individuals  in  the  each  age gender  bin  was 
taken as the representative age of the bin. As a result 
of the binning process, age bins for males and females 
slightly differed. Hence, for analysis which required 
comparison by age across the genders, bins of least 
difference  were  considered  equivalent.  For  each 
measurement,  a  median  was  calculated,  unless 
measurements  were  available  for  less  than  5 
individuals in a particular age gender bin (in which 
case a NULL value was assigned for that biomarker 
in  that  bin,  with  that  age  bin  being  removed  from 
subsequence  analysis).  Each  biomarker  was  than 
scaled  from  0  to  1  for  all  ages  and  each  gender 
separately, and Z transformed for normalization. 
K MEANS  CLUSTERING  AND  MACHINE 
LEARNING: The R implementation of the K means 
algorithm(12)  was  used.  For  the  clustering  of  age 
groups, the number of means (4) was chosen so as to 
include  one  life  period  over  the  trivial  groups 
(growth,  adulthood,  aging).  For  the  biomarkers 
clustering, the number of means (2) was chosen via 
trial and error, with attempts to use larger numbers of 
means  yielded  clusters  that  were  obviously  split  in 
one  gender  compared  other  (i.e. one cluster in one 
gender could be mapped to a pair of clusters in the 
other).  The  clementine  (SPSS,  Chicago,  IL  USA) 
Figure 1.  K means clustering of age groups and blood biomarkers. Males (A) and females (B) from the NHANES3 survey were divided into equal size 
groups (N=150). A derived matrix of row normalized median values for each biomarker in each age group was independently clustered with the K means 
algorithm for each age group, assuming 4 such clusters, and biomarkers, assuming 2 such clusters. Cluster borders are indicated by lines and denominated 
by italics labels on the appropriate axis. The cluster means for men (C) and women (D) in each age group is also shown for the biomarker clusters (red and 
black lines correspondingly). Biomarkers are sorted within each cluster (from top to bottom) in decreasing covariance with the cluster mean, with 1 or 2 
stars indicating biomarkers with r
2≥0.2 or r
2≥0.4, correspondingly. Abbreviations: ACP, serum alpha carotene; BCP, serum beta carotene; BXP, serum beta 
cryptoxanthin; CRP, serum C reactive protein; DWP, platelet distribution width (%); EPP, erythrocyte protoporphyrin; FEP, serum iron; FOP, Serum 
folate; FRP, serum ferritin; GHP, glycated hemoglobin  (%); GRP, granulocyte number (Coulter); GRP%, segment neutrophil (% of 100 cells); HDP, serum 
HDL cholesterol; HGP, hemoglobin; HTP, hematocrit (%); LMP, lymphocyte number (Coulter); LMP%, lymphocytes (% of 100 cells); LYP, serum 
lycopene; LUP, serum lutein/zeaxanthin; MCP, mean cell hemoglobin; MHP, mean cell hemoglobin concentration; MOP, mononuclear number (Coulter); 
MOP%, monocytes (% of 100 cells); MVP, mean cell volume; PBP, serum lead; PLP, platelet count; PVP, mean platelet volume; PXP, serum transferrin 
saturation; RBP, RBC folate; RCP, red blood cell count; REP, serum sum retinyl esters; RWP, red cell distribution width; TCP, serum cholesterol; TGP, 
serum triglycerides; TIP, serum TIBC; VAP, serum vitamin A; VEP, serum vitamin E; WCP, white blood cell count. 
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implementation  of  ANN  and  MLR  was  used  for 
machine learning. 
SUPPLEMENTARY  MATERIALS:  A  complete 
description of the algorithms and procedures used in 
this  work  are  provided  in  the  following  website: 
http://bioinfo.bgu.ac.il/rubin/Misc/rtbi.supp.htm. 
In  this  website,  scripts  are  provided  (for  R  and 
Clementine)  that  produce  all  the  results  from  raw 
NHANES3 data, as well as some of the outputs (i.e. 
the age specific medians used to generate figures 1 
and 2). 
Results 
The  normal  values  of  37  clinical  biomarkers  from 
different age gender groups were estimated from the 
NHANES3  survey.  The  standard normal  scaled 
medians of age gender bins were clustered using the 
K means  algorithm  (Figure  1).  The  basic  temporal 
structure of the data was faithfully reproduced despite 
the use of a non temporal clustering algorithm, with 
consecutive ages clustering together. Age groups that 
cluster together are more similar (in their biomarker 
profile) to each other than to other age groups; the 
border  between  two  clusters  may  thus  point  to  a 
change  points  in  human  development,  in  which 
multiple  biomarkers  change.  The  change  points 
indicated  from  blood  biomarkers  clustering  involve 
12.7, 24.3 and 54.8 years for males and 11.5, 30.3 
and  50  years  for  females.  In  terms  of  biomarkers 
clustering,  the  resulting  clusters  were  generally 
consistent between males and females. Clusters MB 
II  and  FB II  were  highly consistent,  with  all  but  3 
biomarkers  joined  in  males  also  joined  in  the 
corresponding  female  cluster,  and  with  those 
biomarkers that were relatively highly correlated with 
their  respective  cluster  means  (i.e.  r
2≥0.4,  marked 
with  two  stars  in  Figure  1)  in  either  gender  being 
found both clusters without exception. Clusters MB I 
and  FB I  were  less  consistent,  with  MB I  being 
bigger  than  FB I  (17  biomarkers  compared  to  13). 
Nevertheless,  10  biomarkers  are  common  to  both 
clusters  (58%  and  77%  of  MB I  and  FB I 
correspondingly), and 100% of the 6 key biomarkers 
were  found  in  both  clusters  (i.e.,  biomarkers  with 
r
2≥0.2 with their corresponding cluster mean in either 
gender; denoted by 1 2 stars in Figure 1).Despite the 
similarities amongst the clustering of biomarkers by 
age, gender differences in the overall trend of each 
cluster  were  also  observed  (Figure  1C  and  1D), as 
were  differences  in  the  strength  of  the  correlation 
between each biomarker to its cluster mean (Figure 
1A and 1B). In males, cluster MB I exhibited a sharp 
decline in ages 4 to 20, which was also observed in 
FB I,  but  the  moderate  increase,  or  no  change, 
observed in ages higher than 20 years for cluster MB 
I were not observed in cluster FB I. Cluster MB II 
showed  a  near linear  increase  during  ages  4 20, 
which  was  also  observed  in  cluster  FB II,  but  the 
decline in the rate of increase and saturation observed 
in cluster MB II starting at 20 years of age, was not 
observed  in  cluster  FB II,  which  presents  no  clear 
shift in trend at the age of 20 years. Differences were 
also  in  the  strength  of  correlation  between  each 
biomarker  and  its  corresponding  cluster  mean. 
Several  biomarkers  with  a  high  coefficient  of 
correlation  (r
2≥0.4)  in  one  gender  only  showed 
moderate  (0.2≤r
2≤0.4)  coefficient  of  correlation  in 
the other. For example, serum lead levels (PBP) has a 
higher  coefficient  of  correlation  in  males  than  in 
females (r
2 of 0.3 and 0.11 correspondingly; data not 
shown).  
The gender specific patterns of change in biomarkers 
were  further  perused  using  time course  plots  that 
directly compare changes of each biomarker over the 
lifetime  of  males  and  females  (Figure  2).  In  this 
figure, diagonal lines, such as observed for clusters 
FA I  and  MA I  in  serum  lead  levels  (Figure  2A), 
indicate  a  concordant  trend  in  both  genders. 
Horizontal  or  vertical  lines,  such  as  observed  for 
serum vitamin A levels (Figure 2B) in clusters FA III 
and MA III, indicate larger variation in one gender 
relative  to  the  other.  If  the  lines 'double back', this 
indicates  random  variation  in  one  group  but  little 
variation in the other; if the lines are drawn as 'dots 
on a string', they indicate the existence of a trend in 
one  gender,  with  little  or  no  change  in  the  other. 
Areas  characterized  by  non ordered  shifts  in  path 
direction indicate no trend in either gender, such as 
observed for platelet counts in all of cluster FA III 
and  all  of  cluster  MA III.  These  three  examples 
suggest  that  changes  in  relative  biomarkers  levels 
follow a complex and non linear pattern of change.  
This  suggestion  was  further  pursued  by  using 
machine  learning  methods  to  predict  age  from 
biomarkers  measurements.  The  nature  of  the 
dependency between age and blood biomarkers was 
gauged by comparing the performance of linear and 
non linear.  The  performance  of  Artificial  Neural 
Network (ANN), which can model highly non linear 
relationships,  was  compared  to  Multiple  Linear 
Regression (MLR), a predictors that is best suited for 
linearly  seperable  data.  The  NHANES3  population 
was thus studied, training ANN and MLR models on 
2/3rds of the data and testing on the remaining 1/3. 
The  coefficients  of  correlation  shows  that  ANN 
outperformed  MLR  (Table  1),  but  only  if  children 
and adults are mixed. Comparing the performance of 
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ANN  and  MLR  for  adults  only,  using  increasingly 
homogenous  age  groups  (Table  1)  showed  that  for 
adults  >20  years  old,  ANN  performance  was  only 
marginally better than MLR, with the gap becoming 
even  smaller  as  the  age  span  is  restricted  to  older 
individuals. 
 
Age threshold  N  ANN  MLR 
0  4,174  0.832  0.666 
20  2,484  0.594  0.504 
40  1,514  0.437  0.353 
Table 1. Linear and non linear prediction of age from biomarkers. 
Male ages were predicted by training a linear model (MLR) and a 
non linear model  (ANN) on a  training set  from the NHANES3 
data, and applying them to a test set. The number of individuals 
(N) and the correlation coefficient (r
2) between the predicted and 
observed ages are given for each classifier. 
Discussion  
The  relationship  between  age,  gender  and  blood 
biomarkers  was  studied  utilizing  data  from  the 
NHANES3  survey.  Adopting  a  quick  and  naïve 
bioinformatics approach to the analysis allowed us to 
make many observations regarding human growth and 
aging which can later be checked with more rigorous 
methodologies. Using K means clustering to cluster 
age  groups  according  to  their  similarity  in  median 
biomarker  levels,  some  points  in  the  human  life 
course  were  shown  to  be  reflected  in  the  blood 
biomarker  profile  (Figure  1).  Some  of  the  change 
points  found  by  clustering  may  correspond  to  well 
characterized physiological processes (e.g. ages 11.5 
and 12.7 for males and females corresponding to the 
peak of growth at puberty, occurring at ages 11.5 and 
13.5  correspondingly(13);  age  50  in  females 
corresponding  to  menopause,  with  a  median  at  50 
51(14);  age  24.3 in males corresponding to growth 
completion at 25). The remaining critical ages (31.3 
in  females  and  54.8  in  men)  may  represent  novel 
critical ages, or an artifact of the K means clustering 
algorithm. Clustering of biomarkers across the ages, 
on  the  other  hand,  defines  a  grouping  of  blood 
biomarkers,  involving  trivial  biomarkers 
combinations  (such  as  serum  level  of  beta 
cryptoxanthin and lycopene), but also including some 
intriguing relations, such as the clustering of lead with 
specific  vitamins  (vitamins  A  and  E).  Such 
observations  can  potentially  impact  many  research 
areas. For example, it may encourage specific models 
of age dependent changes in population serum lead 
levels(15).  
The  direct  comparison  of  life course  changes  in 
individual biomarker between males and females was 
demonstrated  as  a  potential  tool  for  uncovering 
gender specific  trends  (Figure  2).  This  analysis 
suggested  the  biomarkers  interact  non linearly  with 
age; this observation could be further persued thanks 
to  the  large  sample  size  NHANES3  provides. 
Comparing  linear  and  non linear  models  using 
increasing  age  thresholds  showed  that  the  non 
linearity of biomarker age interactions can largely be 
attributed to the shift from growth to aging (Table 1).  
The analysis presented here is naïve in many ways. K 
means clustering is hardly the most sensitive or robust 
clustering  algorithm.  For  the  biomarkers  clustering, 
for example, temporal algorithms (e.g. (16)) are likely 
to  provide  more  sensitive  and  reliable  results. 
Moreover, proper statistical scrutiny still needs to be 
applied  the  findings  before  they  are  to  be  further 
considered.  Nevertheless,  this  naïve  analysis 
demonstrates  how  the  bioinformatics  tools  can  be 
directly applied to clinical data, and that clear trends 
can  be  identified  in  clinical  data  without  the  tight 
control that only prospective studies or model animals 
provide.  
How suitable is bedside data for the type of analysis 
presented  here?  A  debate  about  its  usefulness  for 
other  applications,  such  as  laboratory  reference 
values calculation(17), provides useful lessons. At the 
heart of the debate is the potential impact of outlier 
patients  on  estimated  95%  population  intervals, 
information that is critical to the care giver but not the 
basic  biologist.  As  demonstrated  here,  biological 
trends can be identified using the median, which is 
much more robust to outliers; it can thus be expected 
that if bedside data is even marginally successful in 
determining 95% intervals, bedside data can be very 
useful for the less demanding job of trend and pattern 
analysis. Bedside data also offers its own advantages 
over  public  surveys,  such  as  involving  huge 
populations  with  possibly  better  coverage  of  older 
ages.  In  addition,  bedside  data  contains  multiple 
measurements  for  the  same  individual,  which  can 
greatly  improve  variation  estimates, and as a result 
may allow better quantitative models to be developed.  
To  conclude,  we  demonstrate  how  classical 
bioinformatics  approaches  can  serve  to  exploit 
clinical data for the study of human biology. As such, 
we  show  that  reverse TBI  can  contribute  to  basic 
research by opening up new and unique sources of 
data. 
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Figure 2. Gender differences in biomarker changes during growth and aging. The age specific median of serum lead levels (A), platelet counts 
(B), and serum vitamin A levels (C) is plotted for males (X axis) and females (Y axis). Each value was z transformed (i.e. subtracting the mean 
and dividing the difference by the standard deviation of the each biomarker). Each point represents a comparison of similar age bins in the two 
genders, and is connected with a line to the previous and next age group. The shape of each point represents the cluster it belongs to in males 
(MA I, plus; MA II, diamond; MAfli III, X; MA IV, dot), and its color represents females clusters (FA I, green; FA II, blue; FA III, red; FA IV, 
black).
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